Effects of extending the time window of thrombolysis to 4.5 hours : Observations in the swedish stroke register (riks-stroke)

Stroke

Volumn 42, Issue 9, 2011, Pages 2492-2497

  Asplund, Kjell ^a   Glader, Eva Lotta ^a   Norrving, Bo ^b   Eriksson, Marie ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

acute ischemic stroke; delay of treatment; implementation; rtPA; thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SWEDEN; THERAPY; TIME OF TREATMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; STROKE; SWEDEN; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 80052414466     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.618587     Document Type: Article

References (22)

1. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;4:CD000213.
2. Wardlaw JM, Sandercock PA, Murray V. Should more patients with acute ischaemic stroke receive thrombolytic treatment? BMJ. 2009;339:b4584.
3. Ferrari J, Knoflach M, Kiechl S, Willeit J, Matosevic B, Seyfang L, et al. Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry. Stroke. 2010;41:2001-2004.
4. Mustanoja S, Meretoja A, Putaala J, Viitanen V, Curtze S, Atula S, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke. 2011;42:102-106.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
6. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303-1309.
7. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40:2438-2441.
8. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
9. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9:866-874.
10. Mihout M, Cordonnier C, Girard-Buttaz I, Leys D. Thrombolysis for ischaemic stroke: impact of the extension of the time-window in daily practice. J Neurol Neurosurg Psychiatry. 2010 Dec 16 [Epub ahead of print].
11. Eriksson M, Jonsson F, Appelros P, Asberg KH, Norrving B, Stegmayr B, et al. Dissemination of thrombolysis for acute ischemic stroke across a nation: experiences from the Swedish stroke register, 2003 to 2008. Stroke. 2010;41:1115-1122.
12. Socialstyrelsen. Nationella riktlinjer för strokesjukvård 2009 [in Swedish]. Available at: www.socialstyrelsen.se/ nationellariktlinjerforstrokesjukvard. Accessed February 17, 2011.
13. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351.
14. Appelros P, Hogeras N, Terent A. Case ascertainment in stroke studies: the risk of selection bias. Acta Neurol Scand. 2003;107:145-149.
15. Glader E-L. Stroke care in Sweden. Hospital care and patient follow-up based on Riks-Stroke, the national quality register for stroke care. PhD thesis, Umeå University Medical Dissertations, New Series No. 838; 2003.
16. Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry. 2011; 82:14-19.
17. Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. Circulation. 2007;115:833-839.
18. Dallongeville J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart. 2010;96: 1744-1749.
19. Lindsberg PJ, Happola O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology. 2006;67:334-336.
20. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
21. Del Zoppo GJ, Saver JL, Jauch EC, Adams HPJ. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
22. European Stroke Organisation. Guidelines for stroke management. Specific treatment: thrombolysis. Available at: www.eso-stroke.org/pdf/ESO-Extended- Thrombolysis-KSU.pdf. Accessed February 17, 2011.